Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in recurrent glioma
NCT05297864Phase 2Terminated
- Sponsor
- University of Oklahoma
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in glioma, glioblastoma (GBM), astrocytoma, Oligodendroglioma (OG), sponsored by University of Oklahoma. Started Jun 2022; status: terminated.
02
Drugs
niraparib
03
Conditions
gliomaglioblastoma (GBM)astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05297864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297864.